Journal article
Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation : Results at three years
Transplantation, Vol.75(12), pp.2048-2053
2003
DOI: 10.1097/01.TP.0000069831.76067.22
PMID: 12829910
Abstract
Two hundred twenty-three recipients of first cadaveric kidney allografts were randomized to receive tacrolimus (TAC) + mycophenolate mofetil (MMF), TAC + azathioprine (AZA), or cyclosporine (Neoral; CsA) + MMF. All regimens contained corticosteroids, and antibody induction was used only in patients who experienced delayed graft function (DGF). Patients were followed-up for 3 years.
Results.
The results at 3 years corroborate and extend the findings of the 2-year results. Patients with DGF treated with TAC+MMF experienced an increase in 3-year allograft survival compared with patients receiving CsA+MMF (84.1% vs. 49.9%, P =0.02). Patients randomized to either treatment arm containing TAC exhibited numerically superior kidney function when compared with CsA. During the 3 years, new-onset insulin dependence occurred in 6, 3, and 11 patients in the TAC+MMF, CsA+MMF, and TAC+AZA treatment arms, respectively. Furthermore, patients randomized to TAC+MMF received significantly lower doses of MMF as compared with those who received CsA+MMF.
Conclusion.
All three immunosuppressive regimens provided excellent safety and efficacy. However, the best results overall were achieved with TAC+MMF. The combination may provide particular benefit to kidney allograft recipients with DGF. In patients who experienced DGF, graft survival was better at 3 years in those patients receiving TAC in combination with either MMF or AZA as compared with the patients receiving CsA with MMF.
Details
- Title: Subtitle
- Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation : Results at three years
- Creators
- Thomas GONWA - Mayo Clinic Transplant Center, Jacksonville, FL, United StatesClaudia CORWIN - Univeristy off Iowa, Iowa City, IA, United StatesRobert METZGER - Translife, Orlando, FL, United StatesChristopher JOHNSON - Medical College of Wisconsin, Milwaukee, WI, United StatesJohn SCANDLING - Stanford University, Palo Alto, CA, United StatesJohn SORENSEN - Latter Day Saints Hospital, Salt Lake City, UT, United StatesLaura MULLOY - Medical College of Georgia, Augusta, CA, United StatesJimmy LIGHT - Washington Hospital, Washington, United StatesGabriel DANOVITCH - University of California at Los Angeles, Los Angeles, CA, United StatesMichael WACHS - The EMMES Corporation, Rockville, MD, United StatesPaul VANVELDHUISEN - The EMMES Corporation, Rockville, MD, United StatesMaryanne LEONHARDT - Fujisawa Healthcare, Inc., Deerfield, IL, United StatesWilliam E FITZSIMMONS - Fujisawa Healthcare, Inc., Deerfield, IL, United StatesNasimul AHSAN - Robert Wood Johnson Medical School, New Brunswick, NJ, United StatesEdward J ALFREY - Milton S. Hershey Medical Center, Harrisburg, PA, United StatesPhilip HALLORAN - University of Alberta, Edmonton, Alberta, CanadaMark STEGALL - University of Colorado, Denver, CO, United StatesMark HARDY - Columbia Presbyterian, New York, NY, United StatesCharles III SHIELD - Via Christi Medical Center, Wichita, KS, United StatesLeslie ROCHER - William Beaumont Hospital, Royal Oak, MI, United States
- Resource Type
- Journal article
- Publication Details
- Transplantation, Vol.75(12), pp.2048-2053
- DOI
- 10.1097/01.TP.0000069831.76067.22
- PMID
- 12829910
- NLM abbreviation
- Transplantation
- ISSN
- 0041-1337
- eISSN
- 1534-6080
- Publisher
- Lippincott
- Language
- English
- Date published
- 2003
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
- Record Identifier
- 9984094566802771
Metrics
8 Record Views